| Browse All

BeyondSpring Inc. (BYSI)

Healthcare | Biotechnology | Florham Park, United States | NasdaqCM
1.74 USD -0.04 (-1.988%) ⇩ (April 21, 2026, 12:21 p.m. EDT)

Short-term: ★★★☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★☆☆☆☆
Hot Take | April 19, 2026, 6:33 p.m. EDT

BeyondSpring is a long-term fundamental trap ($32M debt vs $144WOO cash as interpreted from context, or rather, a balance sheet with negative book value of -$0.798 and negative EPS—but with a massive 88-short ratio bullish signal) dragging it down. Technically, the massive short ratio implies a potential short squeeze, and the options flow is overcrowded to the upside, attempting to pin the stock at $2.50. Until there is real营收 (revenue growth) or a massive re-rating from the cash position, 'buy' is wrong; 'watch' is the only correct move. Avoid the high volatility and low volume.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.082821
AutoETS0.083785
AutoARIMA0.083786
AutoTheta0.115447

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 80%
H-stat 0.25
Ljung-Box p 0.000
Jarque-Bera p 0.234
Excess Kurtosis -0.86
Attribute Value
Sector Healthcare
Market Cap 71,552,840
Forward P/E -3.70
Beta 0.51
Website https://beyondspringpharma.com

As of April 19, 2026, 6:33 p.m. EDT: Call volume and Open Interest (OI) are concentrated significantly in out-of-the-money strikes (2.5, 5.0, 7.5), hemming in OI between $1.73 (near-term high) and $7.50+. This creates a distinct upside bias or bullish gamma exposure, suggesting speculators are positioning for a hypothetical break of $1.73. Conversely, put activity is sparse and centered at the $2.50 strike, indicating limited hedging demand below the current price. The lack of data for May expiration calls suggests a lack of immediate interest in near-term rallies, but the presence of July calls creates a 'wall' at the $2.50 strike.


Info Dump

Attribute Value
52 Week Change 0.30514705
Address1 100 Campus Drive
Address2 4th Floor, Suite 410 West Side
All Time High 48.49
All Time Low 0.542
Ask 1.61
Ask Size 2
Average Daily Volume10 Day 10,030
Average Daily Volume3 Month 20,977
Average Volume 20,977
Average Volume10Days 10,030
Beta 0.506
Bid 1.48
Bid Size 1
Book Value -0.798
City Florham Park
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.74
Current Ratio 1.538
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.8
Day Low 1.68
Display Name BeyondSpring
Earnings Timestamp 1,774,441,800
Earnings Timestamp End 1,778,616,000
Earnings Timestamp Start 1,778,616,000
Ebitda -8,858,000
Ebitda Margins 0.0
Enterprise To Ebitda -7.782
Enterprise Value 68,930,016
Eps Forward -0.47
Eps Trailing Twelve Months -0.21
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.5594
Fifty Day Average Change 0.18060005
Fifty Day Average Change Percent 0.11581381
Fifty Two Week Change Percent 30.514706
Fifty Two Week High 3.44
Fifty Two Week High Change -1.7
Fifty Two Week High Change Percent -0.49418604
Fifty Two Week Low 1.21
Fifty Two Week Low Change 0.53
Fifty Two Week Low Change Percent 0.4380165
Fifty Two Week Range 1.21 - 3.44
Financial Currency USD
First Trade Date Milliseconds 1,489,069,800,000
Float Shares 31,689,400
Forward Eps -0.47
Forward P E -3.7021277
Free Cashflow 15,030,375
Full Exchange Name NasdaqCM
Full Time Employees 44
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.14893
Held Percent Institutions 0.14559
Implied Shares Outstanding 41,122,320
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Long Name BeyondSpring Inc.
Market us_market
Market Cap 71,552,840
Market State REGULAR
Max Age 86,400
Message Board Id finmb_409784135
Most Recent Quarter 1,767,139,200
Net Income To Common -8,473,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 73,000,016
Open 1.68
Operating Cashflow -19,769,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 646 305 6387
Previous Close 1.7753
Price Hint 4
Price To Book -2.1804512
Profit Margins 0.0
Quick Ratio 0.925
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.035300016
Regular Market Change Percent -1.9883972
Regular Market Day High 1.8
Regular Market Day Low 1.68
Regular Market Day Range 1.68 - 1.8
Regular Market Open 1.68
Regular Market Previous Close 1.7753
Regular Market Price 1.74
Regular Market Time 1,776,788,500
Regular Market Volume 4,029
Return On Assets -0.18559
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 41,119,820
Shares Percent Shares Out 0.053400002
Shares Short 2,196,528
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 2,231,450
Short Name BeyondSpring, Inc.
Short Percent Of Float 0.0644
Short Ratio 88.01
Source Interval 15
State NJ
Symbol BYSI
Total Cash 12,561,000
Total Cash Per Share 0.305
Total Debt 320,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.21
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.800125
Two Hundred Day Average Change -0.060124993
Two Hundred Day Average Change Percent -0.033400454
Type Disp Equity
Volume 4,029
Website https://beyondspringpharma.com
Zip 7,932